Clinical Trial

Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer

Study acronym: Subito
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Investigator-initiated, international, multicentre, randomized, open-label, (neo)adjuvant phase III study in target population (stage III, HER2-negative, BRCA1-like breast cancer patients) comparing optimized standard-dose chemotherapy with intensified, alkylating chemotherapy with stem cell rescue.
Protocol Amendment History 19 amendments
This ClinicalTrials.gov record has been amended 19 times since 2016-06-20; most recent amendment 2026-05-28.
Status change: Recruiting → Active, Not Recruiting 2023-11-21
Status change: Active, Not Recruiting → Recruiting 2017-01-25
Status change: Not Yet Recruiting → Active, Not Recruiting 2016-12-19
Trial Details
NCT Number NCT02810743
Lead Sponsor The Netherlands Cancer Institute
Conditions Breast Cancer
Enrollment 174 participants
Start Date 2017-01-25
Primary Completion 2024-07-18 (estimated)
Study Completion 2033-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-01